June 24, 2014
11:00 a.m. to 12:00 pm EDT
Sponsored by
Webinar Description:
Pulmonary disease is among the leading causes of death in the United States and is responsible for more than $150 billion in healthcare costs; with increasing incidences of COPD, asthma and idiopathic pulmonary fibrosis the need to develop innovative therapeutic options for the treatment of these inflammatory lung diseases is imperative. Due to the unique mechanical nature of the lung, the interdependence of lung mechanics and pulmonary inflammation, a relevant translational model must evaluate not only the inflammation but how the underlying disease affects the mechanical properties of the lung. This webinar will showcase translational and predictive animal models of pulmonary disease that focus on both the underlying inflammatory process as well as how the degree and type of inflammation influence change in lung compliance and airway hyperactivity. Additionally, the webinar will provide an overview of each clinical condition and how the utilization of both traditional and functional analyses in our animal models result in outcomes that will best predict how your therapeutic will behave in the clinic.
Learning Objectives:
- Understanding of inflammatory processes and airway hyperreactivity during asthma and characterization of three mouse models of allergic asthma.
a. Ovalbumin model of allergic asthma
b. House dust mite model
c. Cockroach allergen model - Introduction of relevant models of acute lung injury and accompanied decrease in lung compliance
a. Lipopolysaccharide induced lung injury
b. Hydrochloric acid induced lung injury - Characterization of the bleomycin induced lung fibrosis model with a focus on correlation between lung mechanics and collagen deposition as well as 3-D imaging of fibrosis as a terminal endpoint
Speaker Information
Stephen P. Arold, Ph.D., Scientist, Biomodels, LLC
Dr. Arold completed his Ph.D. in Biomedical Engineering from Boston University where he focused on alterations in lung structure and function resulting from inflammation during acute and chronic pulmonary disease. Since then Dr. Arold has more than seven years of experience in industry and academic settings utilizing in vivo and ex vivo models of inflammatory lung disease. As Biomodels’ lead pulmonary scientist, Dr. Arold has successfully developed and validated clinically relevant and translatable models of acute lung injury, acute respiratory distress syndrome, chronic obstructive pulmonary disease, chronic asthma, lung fibrosis as well as bacterial pneumonia has provided a platform for meaningful efficacy studies of new therapies.
David M. Weinstein, Ph.D., President & COO, Numira Inc.
Dr. Weinstein serves as Numira’s President and Chief Operating Officer and has over 20 years of experience in image processing and software development for biomedical imaging. The innovative 3D visualization and analytic tools developed by Dr. Weinstein’s team at Numira have supported leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation. Prior to the acquisition by Numira, he was the President and Chief Technology Officer for Visual Influence, Inc., a company formed in 2001 to focus primarily on exporting technology from the University of Utah’s Scientific Computing and Imaging Institute to commercial applications. Dr. Weinstein received his Ph.D. in computer science from the University of Utah and B.S. degrees in computer science and mathematics from U.C. Berkeley.
Cost: No cost